Current Report Filing (8-k)
January 25 2021 - 06:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
January
19, 2021
Date
of report (date of earliest event reported)
MusclePharm
Corporation
(Exact
name of registrant as specified in its charter)
Nevada |
|
000-53166 |
|
77-0664193 |
(State
or other jurisdictions of
incorporation
or organization)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
4500 Park Granada, Suite 202, Calabasas, CA
91302
(Address
of principal executive offices) (Zip Code)
(800) 292-3909
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrants
under any of the following provisions:
[ ] |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
[ ] |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
N/A
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
|
Emerging growth company
[ ] |
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[ ]
Item
5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Effective
January 19, 2021, the Board of Directors (the “Board”) of
MusclePharm Corporation (the “Company”) appointed Michael Heller to
serve as a director until the Company’s 2021 annual meeting of
stockholders or his earlier death, resignation or removal. The
Company expects Mr. Heller to serve on the Board’s Audit Committee,
Compensation Committee and Nominating and Corporate Governance
Committee.
Mr.
Heller will be compensated for his service as a director in
accordance with the Company’s non-employee director compensation
policy. The Company plans to enter into an indemnification
agreement with Mr. Heller, which will provide him with
indemnification in connection with his service as a member of the
Board.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
MUSCLEPHARM
CORPORATION |
|
|
|
|
By: |
/s/
Ryan Drexler |
|
Name: |
Ryan
Drexler |
|
Title: |
Chief
Executive Officer |
Date:
January 22, 2021